Xeris Biopharma receives USPTO Notice of Allowance for XP-8121 patent application

Xeris Biopharma Holdings, Inc.

Patent allowance covers XP-8121 formulation for hypothyroidism, a novel product candidate.
Notice of Allowance indicates patentability; U.S. patent expected after administrative steps.
CEO John Shannon highlights milestone for meeting unmet medical need in hypothyroidism.
Xeris continues pursuing additional U.S. and international IP protection for LT4 technology.
XP-8121 leverages XeriSol platform for subcutaneous injection of difficult-to-formulate drugs.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.